DITROPAN
LOE ApproachingNDAORALTABLET
Approved
Jul 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
4/8 — Partial
DITROPAN by Johnson & Johnson is clinical pharmacology oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Approved for overactive bladder with symptoms of urge urinary incontinence, urgency, frequency and 2 more indications. First approved in 1975.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DITROPAN (oxybutynin chloride) is an oral anticholinergic small molecule approved in 1975 for overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. It exerts direct antispasmodic effects on bladder smooth muscle by inhibiting muscarinic acetylcholine action, increasing bladder capacity and reducing involuntary contractions. The drug is also indicated for pediatric patients aged 6 and older with detrusor overactivity associated with neurological conditions.
LOE Approaching
As LOE approaches, DITROPAN brand team is likely consolidating and shifting focus to line extension (DITROPAN XL) or preparing for generic transition; expect smaller team with emphasis on managed care and specialty pharmacy roles.
Mechanism of Action
CLINICAL PHARMACOLOGY Oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Oxybutynin chloride exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to…
Worked on DITROPAN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.